Clover Health (CLOV) director receives 79,365 RSU-based Class A shares

Rhea-AI Filing Summary

Clover Health Investments, Corp. director reports stock-based award. Director Carladenise Armbrister Edwards received 79,365 shares of Class A Common Stock on January 6, 2026, as part of a time-based restricted stock unit (RSU) grant at a price of $0 per share. These RSUs represent stock that will vest in full on the first anniversary of January 6, 2026, if she continues serving as a director through that date. Following this grant, she beneficially owns 352,592 shares of Class A Common Stock in total, reported as directly held.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Edwards Carladenise Armbrister

(Last) (First) (Middle)

C/O CLOVER HEALTH INVESTMENTS, CORP.

NOT APPLICABLE

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	01/06/2026		A		79,365(1)	A	$0	352,592	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Class A Common Stock underlying an award of time-based restricted stock units (RSUs). The RSUs will vest in full on the first anniversary of January 6, 2026, subject to the Reporting Person's continued service as a director through such vesting date.

Remarks:

	/s/Peter J. Rivas as attorney-in-fact for Carladenise Edwards	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Clover Health (CLOV) report in this Form 4?

The filing reports that director Carladenise Armbrister Edwards acquired 79,365 shares of Clover Health Class A Common Stock on January 6, 2026, through an award of time-based restricted stock units (RSUs) at a price of $0 per share.

Who is the reporting person in the Clover Health (CLOV) Form 4 filing?

The reporting person is Carladenise Armbrister Edwards, who is identified as a director of Clover Health Investments, Corp. and not a 10% owner or officer.

How many Clover Health (CLOV) shares does the director own after this RSU grant?

After the reported RSU-related acquisition, the director beneficially owns 352,592 shares of Clover Health Class A Common Stock, reported as direct ownership.

What are the vesting terms of the RSUs reported in this Clover Health (CLOV) Form 4?

The 79,365 RSUs will vest in full on the first anniversary of January 6, 2026, provided the reporting person continues to serve as a director through that vesting date.

Was this Clover Health (CLOV) insider transaction a purchase or a grant?

The transaction is coded as “A” (acquired) and represents a that convert into Class A Common Stock, rather than an open-market purchase.

Are the Clover Health (CLOV) shares in this Form 4 held directly or indirectly?

The Form 4 indicates the 352,592 shares following the transaction are held under direct (D) ownership by the reporting person.